NASDAQ:VTVT - vTv Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.72 -0.02 (-1.15 %) (As of 05/24/2019 04:00 PM ET)Previous Close$1.74Today's Range$1.65 - $1.7852-Week Range$0.68 - $6.09Volume799,759 shsAverage Volume1.10 million shsMarket Capitalization$86.55 millionP/E RatioN/ADividend YieldN/ABeta-3.79 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated. Receive VTVT News and Ratings via Email Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT Previous Symbol CUSIPN/A CIK1641489 Webhttp://www.vtvtherapeutics.com/ Phone336-841-0300Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.43 million Price / Sales6.96 Cash FlowN/A Price / Cash FlowN/A Book Value($1.15) per share Price / Book-1.50Profitability EPS (Most Recent Fiscal Year)($0.69) Net Income$-7,910,000.00 Net Margins-63.01% Return on EquityN/A Return on Assets-66.37%Miscellaneous Employees52 Outstanding Shares50,319,000Market Cap$86.55 million Next Earnings Date8/2/2019 (Estimated) OptionableNot Optionable vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.26) EPS for the quarter. The biotechnology company earned $0.92 million during the quarter. View vTv Therapeutics' Earnings History. When is vTv Therapeutics' next earnings date? vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, August 2nd 2019. View Earnings Estimates for vTv Therapeutics. What price target have analysts set for VTVT? 1 brokerages have issued 1 year price targets for vTv Therapeutics' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate vTv Therapeutics' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 74.4% from the stock's current price. View Analyst Price Targets for vTv Therapeutics. What is the consensus analysts' recommendation for vTv Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for vTv Therapeutics. What are Wall Street analysts saying about vTv Therapeutics stock? Here are some recent quotes from research analysts about vTv Therapeutics stock: 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (5/2/2019) 2. Northland Securities analysts commented, "We anticipate details to be forthcoming. Trials: vTv Therapeutics indicated in its 10K filing (2/26 post-close) that the Company has initiated start-up activities for an adaptive P2/P3 trial evaluating azeliragon for treatment of mild Alzheimer’s disease (AD) patients with type 2 diabetes. We anticipate the P2 study will likely be comprised of ~100 subjects with mild AD and A1c levels at/above 6.5%, with ~6 month patient dosing. Based upon the previously released subgroup analysis of AD patients with type 2 diabetes in its large P3 STEADFAST Part A study (See Below), we believe a P2 trial w/ ~100 subjects and six month dosing would be sufficient to demonstrate clinical benefit to potentially support a P3 study." (2/27/2019) Has vTv Therapeutics been receiving favorable news coverage? Media stories about VTVT stock have been trending negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. vTv Therapeutics earned a news impact score of -2.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of vTv Therapeutics' key competitors? Some companies that are related to vTv Therapeutics include OptiNose (OPTN), BIOFRONTERA AG/ADR (BFRA), Theratechnologies (THERF), AMAG Pharmaceuticals (AMAG), Keryx Biopharmaceuticals (KERX), Rigel Pharmaceuticals (RIGL), AC Immune (ACIU), Abeona Therapeutics (ABEO), Kindred Biosciences (KIN), Neptune Wellness Solutions (NEPT), Five Prime Therapeutics (FPRX), Kezar Life Sciences (KZR), Beyondspring (BYSI), XBiotech (XBIT) and Merus (MRUS). What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Novavax (NVAX), Viking Therapeutics (VKTX), Idera Pharmaceuticals (IDRA), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and AcelRx Pharmaceuticals (ACRX). Who are vTv Therapeutics' key executives? vTv Therapeutics' management team includes the folowing people: Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)Mr. Stephen L. Holcombe, Pres & CEO (Age 62)Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VPMs. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55) When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. Who are vTv Therapeutics' major shareholders? vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (0.44%), Morgan Stanley (0.04%) and Wedbush Securities Inc. (0.04%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics. Which major investors are buying vTv Therapeutics stock? VTVT stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, Morgan Stanley and Wedbush Securities Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics. How do I buy shares of vTv Therapeutics? Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $1.72. How big of a company is vTv Therapeutics? vTv Therapeutics has a market capitalization of $86.55 million and generates $12.43 million in revenue each year. The biotechnology company earns $-7,910,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe. What is vTv Therapeutics' official website? The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected] MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 250 (Vote Outperform)Underperform Votes: 231 (Vote Underperform)Total Votes: 481MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: How is the discount rate different from the Federal Funds rate? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.